However, common adverse events such as upper respiratory tract infections, diarrhea and nausea were noted to be more common in the brodalumab-treated groups
Patients had a mean age of 58 years and 53% were men
As for adverse events, a similar percentage of participants across the treatment groups experienced the most common side effect of gastrointestinal upset [2]
The incidence of gastrointestinal-related TEAEs with MEDI4166, such as vomiting and nausea, is consistent with the safety profile of other GLP-1 receptor agonists approved for type 2 diabetes [23]
Important update for Nebraska providers: New branding for Arkansas Blue Cross Blue Shield national account members, starting Jan
For individuals on GLP-1 medications, incorporating Omega-3 supplements can provide an added layer of cardiovascular support